Covid-19 has potentially cost Bavarian Nordic EUR 100m
Covid-19 is still a spanner in the works of Bavarian Nordic's existing vaccine business, as more travel vaccinations have been added to its portfolio. Despite this, CFO Henrik Juuel says this remains the right strategic course for the company.
BY ELIZABETH MØNSTED JOHANSEN, TRANSLATED BY DANIEL PEDERSEN
Preparations had been made for the grand transformation of Bavarian Nordic when it acquired the travel vaccines Rabipur and Encepur from Glaxosmithkline in October 2019. Production, however, had barely begun when the Covid-19 pandemic hit.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Bavarian Nordic CEO receives "extraordinary" retention bonus
For subscribers
.jpg)
.jpg&w=384&q=75)
